Literature DB >> 1194266

Inhibition of human factor IXa by human antithrombin.

J S Rosenberg, P W McKenna, R D Rosenberg.   

Abstract

A procedure is presented for the purification of Factor IX from human plasma. The final product is homogeneous as judged by disc gel electrophoresis and sodium dodecyl sulfate gel electrophoresis. Furthermore, it is completely free of other coagulation component activities. Factor IX is converted to its enzymatically active form by the addition of small quantities of Factor IXa in the presence of calcium ions. This activated species is added to purified antithrombin-heparin cofactor and the interaction is studied in the presence and absence of heparin. Antithrombin-heparin cofactor is found to be a progressive, time-dependent inhibitor of Factor IXa and neutralizes approximately 57% of this enzyme's proteolytic activity within 30 min. The addition of heparin dramatically accelerates the rate of this interaction with virtually complete inhibition of Factor IXa occurring within 15 s. Sodium dodecyl sulfate gel electrophoresis of reduced and nonreduced proteins indicates that antithrombin-heparin cofactor functions as a potent inhibitor of Factor IXa by forming an undissociable complex with the enzyme which is stable in the presence of denaturing or reducing agents (or both). This complex represents a 1:1 stoichiometric combination of enzyme and inhibitor. Heparin increases the rate of formation of this complex without affecting its dissociability or stoichiometry.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1194266

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

2.  Cleavage and inactivation of Factor IX by granulocyte elastase.

Authors:  A Takaki; D L Enfield; A R Thompson
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

Review 3.  Mechanism of the anticoagulant action of heparin.

Authors:  I Björk; U Lindahl
Journal:  Mol Cell Biochem       Date:  1982-10-29       Impact factor: 3.396

4.  Low T3 syndrome in patients following major surgery.

Authors:  A Tsuchiya; P E Goretzki; M Gramse; K Joseph; R A Wahl
Journal:  Jpn J Surg       Date:  1985-07

5.  Partial purification and characterization of the multiple molecular forms of staphylococcal clotting activity (coagulase).

Authors:  M W Reeves; M C Drummond; M Tager
Journal:  J Bacteriol       Date:  1981-12       Impact factor: 3.490

6.  The molecular-weight-dependence of the anti-coagulant activity of heparin.

Authors:  T C Laurent; A Tengblad; L Thunberg; M Höök; U Lindahl
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

7.  In vivo behavior of radioiodinated rabbit antithrombin III. Demonstration of a noncirculating vascular compartment.

Authors:  T H Carlson; A C Atencio; T L Simon
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Activation of human factor IX (Christmas factor).

Authors:  R G Di Scipio; K Kurachi; E W Davie
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

9.  Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.

Authors:  A H Schmaier; L D Dahl; A J Rozemuller; R A Roos; S L Wagner; R Chung; W E Van Nostrand
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Enhanced thrombin generation in patients receiving intensive care.

Authors:  G Balakrishnan; J Brownlie; R Webber; B Gibson
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.